Madison Parrot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Madison Parrot has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Venkata Kashyap Yellepeddi
Division of Clinical Pharmacology, Department of Pediatrics, Spencer Fox Eccles School of Medicine University of Utah Salt Lake City Utah USA
2 shared publications - Ariel Tarrell
University of Utah
1 shared publication - Christopher A. Reilly
Department of Pharmacology and Toxicology, Center for Human Toxicology, University of Utah, Salt Lake City, Utah
1 shared publication - Danielle J. Green
Division of Clinical Pharmacology, Department of Pediatrics University of Utah Salt Lake City Utah USA
1 shared publication - Elizabeth Nance
University of Washington
1 shared publication - Hamidreza Ghandehari
University of Utah
1 shared publication
Latest Publications
- Open Access
- 8 September 2026
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 11 (6)
From bench to bedside: Overcoming translational hurdles in nanoparticle research with pharmacokinetic modeling
Nanoparticles represent a major advancement in drug delivery, enhancing stability, solubility, and targeted delivery while reducing non‐specific toxicity. Despite promising preclinical results, few nanoparticle platforms have successfully translated to clinical use due to limited pharmacokinetic (PK) data, off‐target effects, manufacturing complexity, and a lack of long‐term studies. Emphasizing the pivotal role of PK in this development process is essential for harnessing the full therapeutic potential of nanoparticle applications in clinical practice. In this review, we introduce the concept of model‐informed nanoparticle development (MIND), an extension of model‐informed drug development (MIDD) principles to nanomedicine that integrates knowledge of nanoparticle interactions with biological systems and state‐of‐the‐art pharmacokinetic modeling to support evidence‐based decision‐making. Physiologically‐based PK (PBPK) models simulate the absorption, distribution, metabolism, and elimination (ADME) of nanoparticles within the body, incorporating physiological parameters to predict their PK behavior. Population‐based PK (PopPK) models utilize population variability to characterize nanoparticle PK across diverse patient groups, optimizing dosing strategies and personalized medicine approaches. Mechanistic models elucidate the intricate interactions between nanoparticles and biological systems, integrating cellular pathways and disease mechanisms to predict therapeutic outcomes and guide nanoparticle design. Through the MIND framework, these modeling approaches can enhance our understanding of nanoparticle PK, foster innovation in active agent delivery systems, and accelerate nanoparticle translation from research to clinical applications.
- 8 September 2026
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 11 (6)
Open AccessFrom bench to bedside: Overcoming translational hurdles in nanoparticle research with pharmacokinetic modeling
Nanoparticles represent a major advancement in drug delivery, enhancing stability, solubility, and targeted delivery while reducing non‐specific toxicity. Despite promising preclinical results, few nanoparticle platforms have successfully translated to clinical use due to limited pharmacokinetic (PK) data, off‐target effects, manufacturing complexity, and a lack of long‐term studies. Emphasizing the pivotal role of PK in this development process is essential for harnessing the full therapeutic potential of nanoparticle applications in clinical practice. In this review, we introduce the concept of model‐informed nanoparticle development (MIND), an extension of model‐informed drug development (MIDD) principles to nanomedicine that integrates knowledge of nanoparticle interactions with biological systems and state‐of‐the‐art pharmacokinetic modeling to support evidence‐based decision‐making. Physiologically‐based PK (PBPK) models simulate the absorption, distribution, metabolism, and elimination (ADME) of nanoparticles within the body, incorporating physiological parameters to predict their PK behavior. Population‐based PK (PopPK) models utilize population variability to characterize nanoparticle PK across diverse patient groups, optimizing dosing strategies and personalized medicine approaches. Mechanistic models elucidate the intricate interactions between nanoparticles and biological systems, integrating cellular pathways and disease mechanisms to predict therapeutic outcomes and guide nanoparticle design. Through the MIND framework, these modeling approaches can enhance our understanding of nanoparticle PK, foster innovation in active agent delivery systems, and accelerate nanoparticle translation from research to clinical applications.
- Open Access
- 28 August 2026
- Published by Elsevier in SSRN Electronic Journal
Mucoadhesive Gel for Improved Retention Time and Localized Delivery of Atropine to the Oral Cavity
Sialorrhea is often managed with off-label atropine eye drops, but rapid oral clearance can limit drug exposure and require frequent dosing. This study characterized a mucoadhesive atropine sulfate gel and evaluated its physicochemical properties, rheology, in vitro release, mucosal permeation, and relationship to in vivo pharmacokinetics. Atropine sulfate gels (0.01%, 0.05%, and 0.1% w/w) were evaluated using Franz diffusion cells and a dynamic flow-through system with porcine buccal mucosa and simulated saliva. The effects of drug concentration, application dose, salivary flow rate, and temperature were examined, and porcine buccal and sublingual tissues were used to evaluate mucosal retention and permeation. In dynamic testing, atropine eye drop solution released approximately 90% of the drug within 10 min, whereas the gel formulations required approximately 90 min to reach a similar extent of release. Application dose had a greater influence on release kinetics than formulation strength. Atropine was recovered from both buccal and sublingual mucosa but was not detected in the receiver medium during the 6-h permeation study, indicating tissue retention and limited permeation. In vitro release data were combined with clinical pharmacokinetic data to develop an in vitro-in vivo correlation. The model demonstrated a strong relationship between in vitro release and estimated in vivo absorption (R2 = 0.931), with absolute prediction errors of 3.96% and 2.70% for AUC and Cmax, respectively. These findings indicate that the atropine gel provides sustained local delivery and that the in vitro release method may support formulation optimization and prediction of in vivo performance.
- 28 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMucoadhesive Gel for Improved Retention Time and Localized Delivery of Atropine to the Oral Cavity
Sialorrhea is often managed with off-label atropine eye drops, but rapid oral clearance can limit drug exposure and require frequent dosing. This study characterized a mucoadhesive atropine sulfate gel and evaluated its physicochemical properties, rheology, in vitro release, mucosal permeation, and relationship to in vivo pharmacokinetics. Atropine sulfate gels (0.01%, 0.05%, and 0.1% w/w) were evaluated using Franz diffusion cells and a dynamic flow-through system with porcine buccal mucosa and simulated saliva. The effects of drug concentration, application dose, salivary flow rate, and temperature were examined, and porcine buccal and sublingual tissues were used to evaluate mucosal retention and permeation. In dynamic testing, atropine eye drop solution released approximately 90% of the drug within 10 min, whereas the gel formulations required approximately 90 min to reach a similar extent of release. Application dose had a greater influence on release kinetics than formulation strength. Atropine was recovered from both buccal and sublingual mucosa but was not detected in the receiver medium during the 6-h permeation study, indicating tissue retention and limited permeation. In vitro release data were combined with clinical pharmacokinetic data to develop an in vitro-in vivo correlation. The model demonstrated a strong relationship between in vitro release and estimated in vivo absorption (R2 = 0.931), with absolute prediction errors of 3.96% and 2.70% for AUC and Cmax, respectively. These findings indicate that the atropine gel provides sustained local delivery and that the in vitro release method may support formulation optimization and prediction of in vivo performance.
- 4 June 2026
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 53 (4)
Pediatric oral cavity physiologically based pharmacokinetic model to predict pharmacokinetics of mucoadhesive atropine gel to treat sialorrhea
Sialorrhea significantly impairs quality of life in children with neurodisabilities, including cerebral palsy, yet safe and effective pharmacologic treatment options remain limited. Although atropine is widely used for sialorrhea, it is most commonly used off-label as ophthalmic drops administered intraorally, an approach constrained by poor mucosal retention, frequent dosing, medication-error risk, and systemic anticholinergic adverse effects. To address these limitations, we developed a novel mucoadhesive atropine oral gel (0.01% weight/weight (w/w)) to enhance intraoral residence time and support controlled local and systemic exposure. The pharmacokinetics and safety of the atropine gel were evaluated in a Phase I clinical trial in healthy adults, which informed the development and validation of a physiologically based pharmacokinetic (PBPK) model incorporating a mechanistic oral cavity framework. The oral cavity PBPK model accounts for salivary flow, mucosal absorption, swallowing, and saliva-tissue exchange across six compartments, enabling predictions of local and systemic exposure and evaluation of formulation-relevant determinants of intraoral absorption. Pediatric PBPK simulations were scaled from the adult model using Population Estimates for Age-Related Physiology™ (PEAR Physiology™) to support model-informed dose selection. Simulations identified a minimum pediatric dose range of 0.25 mg/kg once or twice daily, with twice-daily dosing to maintain plasma concentrations within the established minimum effective and maximum tolerated concentration range. Collectively, this work demonstrates the utility of PBPK modeling as a translational tool to integrate formulation attributes, oral cavity physiology, and pediatric dose selection, and supports the clinical advancement of mucoadhesive atropine gel as a safer alternative to off-label intraoral atropine eye drops.
- 4 June 2026
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 53 (4)
Pediatric oral cavity physiologically based pharmacokinetic model to predict pharmacokinetics of mucoadhesive atropine gel to treat sialorrhea
Sialorrhea significantly impairs quality of life in children with neurodisabilities, including cerebral palsy, yet safe and effective pharmacologic treatment options remain limited. Although atropine is widely used for sialorrhea, it is most commonly used off-label as ophthalmic drops administered intraorally, an approach constrained by poor mucosal retention, frequent dosing, medication-error risk, and systemic anticholinergic adverse effects. To address these limitations, we developed a novel mucoadhesive atropine oral gel (0.01% weight/weight (w/w)) to enhance intraoral residence time and support controlled local and systemic exposure. The pharmacokinetics and safety of the atropine gel were evaluated in a Phase I clinical trial in healthy adults, which informed the development and validation of a physiologically based pharmacokinetic (PBPK) model incorporating a mechanistic oral cavity framework. The oral cavity PBPK model accounts for salivary flow, mucosal absorption, swallowing, and saliva-tissue exchange across six compartments, enabling predictions of local and systemic exposure and evaluation of formulation-relevant determinants of intraoral absorption. Pediatric PBPK simulations were scaled from the adult model using Population Estimates for Age-Related Physiology™ (PEAR Physiology™) to support model-informed dose selection. Simulations identified a minimum pediatric dose range of 0.25 mg/kg once or twice daily, with twice-daily dosing to maintain plasma concentrations within the established minimum effective and maximum tolerated concentration range. Collectively, this work demonstrates the utility of PBPK modeling as a translational tool to integrate formulation attributes, oral cavity physiology, and pediatric dose selection, and supports the clinical advancement of mucoadhesive atropine gel as a safer alternative to off-label intraoral atropine eye drops.